European shares extended gains on Friday, with Germany's DAX index closing at an all-time high, as signs of easing global ...

Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

European STOXX Europe 600 Index continues its upward trajectory, marking a fourth consecutive week of gains amid easing trade tensions between China and the U.S., small-cap stocks have been ...

Bavarian Nordic has supplied a liquid-frozen formulation of JYNNEOS to the U.S. government for stockpiling since 2010 and in ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q1 2025 Results, Conference Call and Webcast. At this time all participants will be in a listen-only mode. After the speaker ...

European stock markets saw gains. Germany's DAX reached a record high. Investors felt relieved by signs of a possible ease in ...